Synthesis, molecular docking, and in vitro activity of a novel angiotensin-converting enzyme 2 inhibitor, LMS1007: a potential molecule in Covid-19 and cancer treatments
Loai M. Saadah, Ghina’a Abu Deiab, Qosay Ali Al-Balas, Iman A. Basheti · RSC Advances · 2025
) at a concentration of 2.3 mM in all kits. LMS1007, similar to carnosine in breast cancer cell lines, exhibited potential inhibitory effects on the ACE2-mediated host uptake of Covid-19. Thus, a thorough review and discussion are provided on the role of ACE2 as an attractive target for the development of new drugs for Covid-19 treatment.